CENTOCOR, INC.
🇺🇸United States
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-05-26
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00401765
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
Phase 2
Terminated
- Conditions
- Cancer, Prostate
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT00385827
A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).
Completed
- Conditions
- COPDPulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Collection of safety data for Cohort 1
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 88
- Registration Number
- NCT00380796
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2006-08-08
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 643
- Registration Number
- NCT00361335
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
Phase 3
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: infliximab
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00336492
A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2015-04-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT00320216
A Study of the Safety and Efficacy of Golimumab (CNTO 148) in Subjects With Active Rheumatoid Arthritis Previously Treated With Biologic Anti-TNFa Agent(s)
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: PlaceboBiological: Golimumab 100 mgBiological: Golimumab 50 mg
- First Posted Date
- 2006-03-07
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 461
- Registration Number
- NCT00299546
A Study Comparing the Efficacy and Safety of Intracoronary Stenting With or Without Abciximab, an Anti-Platelet Therapy, and Conventional Coronary Angioplasty With Abciximab
Phase 3
Completed
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- Interventions
- First Posted Date
- 2006-01-02
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 2399
- Registration Number
- NCT00271401
A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
Phase 3
Completed
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2015-05-25
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 2792
- Registration Number
- NCT00269880
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
Phase 3
Completed
- Conditions
- Crohn Disease
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT00269841
© Copyright 2025. All Rights Reserved by MedPath